Pattern of use of radiotherapy for lung cancer: a descriptive study

Abstract

BackgroundLung cancer remains one of the most prevalent forms of cancer. Radiotherapy, with or without other therapeutic modalities, is an effective treatment. Our objective was to report on the use of radiotherapy for lung cancer, its variability in our region, and to compare our results with the previous study done in 2004 (VARA-I) in our region and with other published data.MethodsWe reviewed the clinical records and radiotherapy treatment sheets of all patients undergoing radiotherapy for lung cancer during 2007 in the 12 public hospitals in Andalusia, an autonomous region of Spain. Data were gathered on hospital, patient type and histological type, radiotherapy treatment characteristics, and tumor stage.Results610 patients underwent initial radiotherapy. 37% of cases had stage III squamous cell lung cancer and were treated with radical therapy. 81% of patients with non-small and small cell lung cancer were treated with concomitant chemo-radiotherapy and the administered total dose was ≥ 60 Gy and ≥ 45 Gy respectively. The most common regimen for patients treated with palliative intent (44.6%) was 30 Gy. The total irradiation rate was 19.6% with significant differences among provinces (range, 8.5-25.6%; p < 0.001). These differences were significantly correlated with the geographical distribution of radiation oncologists (r = 0.78; p = 0.02). Our results were similar to other published data and previous study VARA-I.ConclusionsOur results shows no differences according to the other published data and data gathered in the study VARA-I. There is still wide variability in the application of radiotherapy for lung cancer in our setting that significantly correlates with the geographical distribution of radiation oncologists.

New Mechanisms of Tumor-Associated Macrophages on Promoting Tumor Progression: Recent Research Advances and Potential Targets for Tumor Immunotherapy

“…It is reported that CD68 + HLA-DR + TAMs in hepatocellular carcinoma (HCC) can promote migration of HCC cells via the NF- κ B/FAK pathway [66]. Specifically, TAM-derived IL-6 and IL-8 enhance invasive activity of LoVo cells induced by PRL-3 in a KCNN4 channel-dependent manner [67]. …”

SIK1-LNC represses the proliferative, migrative, and invasive abilities of lung cancer cells

“… 3 Commonly accepted, radiotherapy, chemotherapy, traditional Chinese medicine, and their conjunctions are the approaches for lung cancer treatment. 4 – 7 Despite significant advances made in research into the progression, development, and prognosis of lung cancer over the past few decades, the outcome of most patients afflicted with lung cancer has not remarkably improved. Recently, researchers have disclosed that the vast majorities of human genome are indeed transcribed into various types of non-coding RNAs (ncRNAs) without protein-coding ability, including small ncRNAs (RNA transcript length <200 nt) and long ncRNAs (lncRNAs, RNA transcript length >200 nt).…”

Pattern of use of radiotherapy for lung cancer: Descriptive study

“…Style of practice: medical practice patterns may explain the low irradiation rates found in our region [36,37]. Most clinical trials have a control arm with standard treatment that does not include RT [38,39].…”